PedAM
Pediatric Disease Annotations & Medicines
| Disease | hepatitis c |
| Symptom | C0040034|thrombocytopenia |
| Sentences | 27 |
| PubMedID- 24531177 | Romiplostim for severe thrombocytopenia in the treatment of chronic hepatitis c virus infection: a new option for clinicians. |
| PubMedID- 25209590 | Eltrombopag is a new thrombopoietin receptor agonist which was used successfully in this critical case of thrombocytopenia associated with hepatitis c infection before it became an approved drug for such cases. |
| PubMedID- 24714308 | Another recent study concluded that anti-p antibodies contribute to thrombocytopenia associated with chronic hepatitis c virus infection . |
| PubMedID- 21188204 | One study demonstrated the presence of increased level of antiplatelet glycoproteins in serum of chronic hepatitis c infected patients with thrombocytopenia . |
| PubMedID- 22312391 | However, thrombocytopenia also occurs in patients with chronic hepatitis c without cirrhosis. |
| PubMedID- 23671722 | Conclusion: attention should be paid to potential thrombocytopenia in the treatment of chronic hepatitis c patients. |
| PubMedID- 19689996 | thrombocytopenia in patients with chronic hepatitis c: a possible role of hcv on platelet progenitor cell maturation. |
| PubMedID- 24731162 | Background and aim: thrombocytopenia (tcp) of chronic hepatitis c patients with cirrhosis has a negative impact on the management of interferon-based treatment. |
| PubMedID- 24621321 | Therefore, this case of severe thrombocytopenia that developed in a patient with chronic hepatitis c treated with peg-ifn/rbv in spite of the patient having the itpa-cc genotype should be kept in mind. |
| PubMedID- 25728497 | Background: there are many potential causes of thrombocytopenia in patients with chronic hepatitis c (chc). |
| PubMedID- 24304453 | thrombocytopenia in patients with chronic hepatitis c may represent an obstacle for the initiation of antiviral treatment. |
| PubMedID- 20720351 | A case of severe thrombocytopenia in a patient with chronic hepatitis c caused by a single administration of pegylated interferon alpha 2a subsequent to 48 weeks of pegylated interferon alpha 2b plus ribavirin therapy. |
| PubMedID- 21120192 | Suggested that thrombocytopenia in patients with hepatitis c infection may be due to a variety of non-immune and immune mechanisms . |
| PubMedID- PMC4034027 | Recent reports suggest that certain polymorphisms in type i ifn signaling molecules are associated with ifn-induced neutropenia and thrombocytopenia in patients with chronic hepatitis c. ifnγ binds to a cell-surface receptor composed of two transmembrane polypeptides ifgr1 and ifgr2 resulting in activation of the janus kinases jak1 and jak2, phosphorylation of stat1, formation of stat1 homodimers, and activation of a specific set of genes that encode the effector molecules responsible for mediating its biological activity. |
| PubMedID- 20796207 | Epidemiology of thrombocytopenia in patients with chronic hepatitis c: more than meets the eye. |
| PubMedID- 20796208 | Prevalence of thrombocytopenia among patients with chronic hepatitis c: a systematic review. |
| PubMedID- 21188328 | Background and aims: thrombocytopenia in patients with chronic hepatitis c may be the result of several factors: bone marrow inhibition, the decrease of liver thrombopoietin production and an autoimmune mechanism. |
| PubMedID- 23001404 | Improvement of thrombocytopenia in hepatitis c-related advanced fibrosis patients after sustained virological response. |
| PubMedID- 20805953 | The increase in platelet counts after pse may also improve the svr rate in chronic hepatitis c patients with thrombocytopenia . |
| PubMedID- 25764686 | thrombocytopenia in patients with chronic hepatitis c represents an obstacle for the initiation of antiviral treatment. |
| PubMedID- 24457056 | We report the case of a 51 - year – old caucasian female who developed a severe, reversible, immune thrombocytopenia associated with hepatitis c virus infection. |
| PubMedID- 24128106 | Eltrombopag for the treatment of thrombocytopenia in patients with chronic hepatitis c: two case reports. |
| PubMedID- 20460556 | Objective: to review the pharmacology and pharmacokinetics and evaluate the safety and efficacy of eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (itp) and thrombocytopenia associated with hepatitis c virus (hcv) cirrhosis. |
| PubMedID- 26417629 | Eltrombopag (revolade ) and thrombocytopenia in patients with hepatitis c. |
| PubMedID- 25331767 | Eltrombopag: a review of its use in the treatment of thrombocytopenia in patients with chronic hepatitis c. |
| PubMedID- 24653754 | In november 2012, the us food and drug administration (fda) approved eltrombopag (promacta), an oral thrombopoietin agonist, for treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of ifn-based therapy. |
| PubMedID- 20731135 | This article represented a modern view on the problem of thrombocytopenia in patients with chronic hepatitis c, including it's role as an adverse event of antiviral therapy. |
Page: 1